Dr Peters current work is focused on use of different antihypertensives, frailty and risk and benefit of treatment in the very elderly.
Between 2010 and 2012 Dr Peters was part of the core team setting up and developing the Imperial Clinical Trials Unit (ICTU). ICTU was launched in 2010 and is a fully UKCRC registered trials unit.
Prior to 2010 she led the multinational HYpertension in the Very Elderly Trial Cognitve function (HYVET-COG) study and co-ordinated the main Hypertension in the Very Elderly [HYVET] trial. HYVET was an Imperial sponsored multinational double blind RCT which was rated ‘Trial of the year’ by the Society for Clinical Trials and an exceptional landmark in medicine(F1000) in 2008. The HYVET trial results have changed global guidelines for the use of antihypertensive treatment in older adults (>=80 years).
Research interests include risk factors for dementia, particularly cardiovascular risk factors and potential interventions to ameliorate or prevent cognitive decline and dementia.
et al., 2022, Diastolic Blood Pressure Variability in Later Life May Be a Key Risk Marker for Cognitive Decline, Hypertension, Vol:79, ISSN:0194-911X, Pages:1037-1044
et al., 2022, Left ventricular hypertrophy and incident cognitive decline in older adults with hypertension, Journal of Human Hypertension, ISSN:0950-9240
et al., 2022, No clear associations between subjective memory concerns and subsequent change in cognitive function: the PATH through life study, European Journal of Ageing, ISSN:1613-9372
et al., 2022, Blood pressure change and cognition in childhood and early adulthood: a systematic review, Therapeutic Advances in Chronic Disease, Vol:13, ISSN:2040-6223
et al., 2022, Reducing the Risk of Cognitive Decline and Dementia: WHO Recommendations, Frontiers in Neurology, Vol:12, ISSN:1664-2295